Plasma chemokines CXCL10 and CXCL9 as potential diagnostic markers of drug-sensitive and drug-resistant tuberculosis
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Plasma chemokines CXCL10 and CXCL9 as potential diagnostic markers of drug-sensitive and drug-resistant tuberculosis
Authors
Keywords
-
Journal
Scientific Reports
Volume 13, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2023-05-06
DOI
10.1038/s41598-023-34530-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cytokine upsurge among drug-resistant tuberculosis endorse the signatures of hyper inflammation and disease severity
- (2023) Pavithra Sampath et al. Scientific Reports
- Study on the Correlation between Interleukin-27 and CXCL10 in Pulmonary Tuberculosis
- (2022) Jiahui Fan et al. Journal of Immunology Research
- Leukocytes from Patients with Drug-Sensitive and Multidrug-Resistant Tuberculosis Exhibit Distinctive Profiles of Chemokine Receptor Expression and Migration Capacity
- (2021) Ranferi Ocaña-Guzmán et al. Journal of Immunology Research
- CXCL1: A new diagnostic biomarker for human tuberculosis discovered using Diversity Outbred mice
- (2021) Deniz Koyuncu et al. PLoS Pathogens
- Plasma chemokines as immune biomarkers for diagnosis of pediatric tuberculosis
- (2021) Nathella Pavan Kumar et al. BMC INFECTIOUS DISEASES
- Serum Biomarker Profile Including CCL1, CXCL10, VEGF, and Adenosine Deaminase Activity Distinguishes Active From Remotely Acquired Latent Tuberculosis
- (2021) Eveline M. Delemarre et al. Frontiers in Immunology
- Effects of host‐directed therapies on the pathology of tuberculosis
- (2020) Liana Tsenova et al. JOURNAL OF PATHOLOGY
- Infant Alveolar Macrophages Are Unable to Effectively Contain Mycobacterium tuberculosis
- (2020) Anu Goenka et al. Frontiers in Immunology
- Plasma chemokines are baseline predictors of unfavorable treatment outcomes in pulmonary tuberculosis
- (2020) Nathella P Kumar et al. CLINICAL INFECTIOUS DISEASES
- Diagnostic value of CXCR3 and its ligands in spinal tuberculosis
- (2020) Xiaoqian Shang et al. Experimental and Therapeutic Medicine
- IP-10 contributes to the inhibition of mycobacterial growth in an ex vivo whole blood assay
- (2019) Ivana Palucci et al. INTERNATIONAL JOURNAL OF MEDICAL MICROBIOLOGY
- Association of chemotactic chemokine ligand 5 rs2107538 polymorphism with tuberculosis susceptibility: A meta-analysis
- (2019) Yun-Feng Sheng et al. Innate Immunity
- IL-18/IL-37/IP-10 signalling complex as a potential biomarker for discriminating active and latent TB
- (2019) Sebastian Wawrocki et al. PLoS One
- Plasma chemokines are biomarkers of disease severity, higher bacterial burden and delayed sputum culture conversion in pulmonary tuberculosis
- (2019) Nathella P. Kumar et al. Scientific Reports
- Expression of USP18 and IL2RA Is Increased in Individuals Receiving Latent Tuberculosis Treatment with Isoniazid
- (2019) Eleane de Oyarzabal et al. Journal of Immunology Research
- Mycobacterial growth inhibition is associated with trained innate immunity
- (2018) Simone A. Joosten et al. JOURNAL OF CLINICAL INVESTIGATION
- Acute phase proteins and IP-10 as triage tests for the diagnosis of tuberculosis: systematic review and meta-analysis
- (2018) V.S. Santos et al. CLINICAL MICROBIOLOGY AND INFECTION
- Accuracy of interferon-γ-induced protein 10 for diagnosing latent tuberculosis infection: a systematic review and meta-analysis
- (2018) X. Qiu et al. CLINICAL MICROBIOLOGY AND INFECTION
- A combination of baseline plasma immune markers can predict therapeutic response in multidrug resistant tuberculosis
- (2017) Selena Ferrian et al. PLoS One
- IP-10 differentiates between active and latent tuberculosis irrespective of HIV status and declines during therapy
- (2015) I. Wergeland et al. JOURNAL OF INFECTION
- IP-10 measured by Dry Plasma Spots as biomarker for therapy responses in Mycobacterium Tuberculosis infection
- (2015) Kristian Tonby et al. Scientific Reports
- Neutrophils from pulmonary tuberculosis patients show augmented levels of chemokines MIP-1α, IL-8 and MCP-1 which further increase upon in vitro infection with mycobacterial strains
- (2014) J. Nancy Hilda et al. HUMAN IMMUNOLOGY
- CXCL5-secreting pulmonary epithelial cells drive destructive neutrophilic inflammation in tuberculosis
- (2014) Geraldine Nouailles et al. JOURNAL OF CLINICAL INVESTIGATION
- Chemokines in tuberculosis: The good, the bad and the ugly
- (2014) Leticia Monin et al. SEMINARS IN IMMUNOLOGY
- Beyond the IFN- horizon: biomarkers for immunodiagnosis of infection with Mycobacterium tuberculosis
- (2013) N. N. Chegou et al. EUROPEAN RESPIRATORY JOURNAL
- How should I interpret an interferon gamma release assay result for tuberculosis infection?: Table 1
- (2013) Ibrahim Abubakar et al. THORAX
- Prospects for Tuberculosis Elimination
- (2012) Christopher Dye et al. Annual Review of Public Health
- IP-10 release assays in the diagnosis of tuberculosis infection: current status and future directions
- (2012) Morten Ruhwald et al. EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
- Plasma cytokines and chemokines differentiate between active disease and non-active tuberculosis infection
- (2012) Adane Mihret et al. JOURNAL OF INFECTION
- CCL2−2518 (A/G) polymorphisms and tuberculosis susceptibility: a meta-analysis [Review article]
- (2011) W-X. Feng et al. INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE
- Profiling Early Lung Immune Responses in the Mouse Model of Tuberculosis
- (2011) Dongwan D. Kang et al. PLoS One
- CCL5 participates in early protection against Mycobacterium tuberculosis
- (2010) Bridget Vesosky et al. JOURNAL OF LEUKOCYTE BIOLOGY
- Genetic association between a chemokine gene CXCL-10 (IP-10, interferon gamma inducible protein 10) and susceptibility to tuberculosis
- (2009) Nelson Leung-Sang Tang et al. CLINICA CHIMICA ACTA
- ESAT6-Induced IFNγ and CXCL9 Can Differentiate Severity of Tuberculosis
- (2009) Zahra Hasan et al. PLoS One
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More